Figure 4.
Biomarker analysis
(A) Genetic landscape of 89 patients with sufficient pretreatment tumor material for targeted NGS.
(B and C) Kaplan-Meier curves of progression-free survival (B) and overall survival (C) for patients with EGFR amplification.
(D) Kaplan-Meier curves of progression-free survival in patients with 11q13 amplification.